ACIU Quote, Trading Chart, AC Immune SA
home / stock / aciu / aciu quote
$3.22 Last:
-1.23% Change Percent:
$3.31 Open:
$3.22 Previous Close:
$3.31 High:
$3.17 Low:
50,032 Volume:
05/27/2022 04:53:21 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
ACIU Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2022-05-27 | 3.31 | 3.22 | 3.31 | 3.17 | 50,032 |
| 2022-05-26 | 3.22 | 3.26 | 3.33 | 3.2 | 42,993 |
| 2022-05-25 | 3.21 | 3.15 | 3.25 | 3.01 | 42,140 |
| 2022-05-24 | 3.33 | 3.25 | 3.38 | 3.18 | 76,166 |
| 2022-05-23 | 3.16 | 3.37 | 3.39 | 3.16 | 96,204 |
| 2022-05-20 | 3.13 | 3.15 | 3.21 | 3 | 101,711 |
| 2022-05-19 | 3.35 | 3.12 | 3.39 | 2.99 | 354,419 |
| 2022-05-18 | 3.08 | 3.2 | 3.27 | 3.08 | 168,783 |
| 2022-05-17 | 3.04 | 3.1 | 3.1049 | 3 | 58,252 |
| 2022-05-16 | 2.86 | 2.99 | 3.06 | 2.84 | 241,900 |
| 2022-05-13 | 2.72 | 2.99 | 3.1 | 2.71 | 154,751 |
| 2022-05-12 | 2.59 | 2.65 | 2.82 | 2.46 | 55,738 |
| 2022-05-11 | 2.73 | 2.54 | 2.78 | 2.53 | 108,366 |
| 2022-05-10 | 2.9 | 2.73 | 3 | 2.7 | 164,259 |
| 2022-05-09 | 3.32 | 2.92 | 3.32 | 2.9031 | 122,729 |
| 2022-05-06 | 3.22 | 3.33 | 3.41 | 3.17 | 49,512 |
| 2022-05-05 | 3.5 | 3.28 | 3.51 | 3.24 | 51,314 |
| 2022-05-04 | 3.4698 | 3.52 | 3.56 | 3.34 | 30,441 |
| 2022-05-03 | 3.46 | 3.55 | 3.64 | 3.44 | 37,904 |
| 2022-05-02 | 3.54 | 3.44 | 3.5445 | 3.3401 | 41,725 |
AC Immune SA Company Name:
ACIU Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
-
LAUSANNE, Switzerland, May 17, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Dr. Andrea Pfeifer, CEO and a Director of AC Immune, will be awarded the prestig...
-
First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first gen...
-
Two clinical readouts delivered in Q1; five more expected by year-end Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this first-in-class anti-pTau vaccine First images of alpha-synuclein in patients’...